Background Betatrophin, a hepatic protein that has been implicated by several studies with a role in promoting pancreatic β-cell proliferation and improving glucose tolerance. Although the exact role of betatrophin and its mechanism of action is still elusive and a matter of controversy, a growing number of reports support betatrophin’s potential yet unclear role in T2DM. Aim: To investigate changes in fasting betatrophin levels following the introduction of a weight loss surgical intervention (Laparoscopic Sleeve gastrectomy, LSG) in morbid-obese, both diabetic and non-diabetic participants during a 1-year follow up. Methods: We compared fasting betatrophin levels at baseline in two cohorts; normal weight and morbid-obese diabetic and non-diabetic participants. To investigate the potential correlation between betatrophin and parameters indicating T2DM remission such as, β-cell function and insulin sensitivity, betatrophin levels were further examined at different post-surgery time points, in the morbid obese cohort. Results: At baseline, an inverse correlation between betatrophin and fasting insulin was seen (r=-0.397, p <0.016). Betatrophin levels were higher in people with diabetes, both morbid-obese (mean=1415 ±196.4 pg/ml, p< 0.03) and normal-weight participants (mean=2231 ±328 pg/ml, p<0.004), compared to non-diabetic morbid-obese (mean=876 ±155 pg/ml), and healthy controls (mean=868.9 ±218.7 pg/ml). Post LSG, basal betatrophin levels showed a gradual increase in morbid-obese diabetic participants. A gradual constant reduction in HbA1c levels was observed in morbid-obese diabetic participants during the year after LSG. The pattern of change in betatrophin demonstrated transient changes; an initial elevation reaching a peak at two months post-LSG, and then restoration of basal levels after one year. Conclusion: pre-surgery fasting betatrophin levels suggest a potential association between an increased betatrophin level and T2DM. This is reflected through having the highest levels of fasting betatrophin in diabetic participants, both obese and normal-weight. Post-LSG, fasting betatrophin demonstrates a unique pattern of change, showing a short-term increase followed by a long-term decrease restoring basal levels of betatrophin. The detected change in fasting betatrophin level post-LSG in morbid-obese diabetic participants, implicates a potential association to the observed improvement in insulin sensitivity, reflected by iHOMA2%S. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03038373.
|Publication status||Published - 4 Dec 2017|
|Event||International Diabetes Federation - Abudhabi , Abudhabi , United Arab Emirates|
Duration: 4 Dec 2017 → 8 Dec 2017
Conference number: 23
|Conference||International Diabetes Federation|
|Country||United Arab Emirates|
|Period||4/12/17 → 8/12/17|
- Bariatric surgery
- type 2 diabetes mellitus
Alshawaf, E., Al Ozairi, E., Al-Asfar, F., & Arefanian, H. (2017). Fasting Betatrophin, 1-year post Laparoscopic Sleeve Gastrectomy, a correlation to beta cell function & T2DM remission. Poster session presented at International Diabetes Federation , Abudhabi , United Arab Emirates.